57 Additionally, IL-35 can induce the generation of a regulatory population from naive mouse or human CD4+ T cells. These so-called iT(R)35 cells mediate suppression via IL-35 alone, do not express Foxp3 and are strongly suppressive and stable in vivo. 58 In both dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid colitis, recombinant IL-35 therapy can treat disease through downregulation of the Th1 and Th17 master transcription factors, T-bet and RORC (related orphan receptor C), respectively, and through inhibition of IFN-γ, IL-6 and IL-17.59 The gene discussed is CD4; the disease is colitis.